bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Other Long-Term Assets
bluebird bio Inc
Other Long-Term Assets Peer Comparison
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Other Long-Term Assets
$50.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
43%
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$9.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
51%
|
CAGR 10-Years
27%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$4.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
39%
|
CAGR 10-Years
19%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$2.8B
|
CAGR 3-Years
49%
|
CAGR 5-Years
13%
|
CAGR 10-Years
75%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
55%
|
CAGR 5-Years
27%
|
CAGR 10-Years
29%
|
See Also
What is bluebird bio Inc's Other Long-Term Assets?
Other Long-Term Assets
50.8m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Other Long-Term Assets amounts to 50.8m USD.
What is bluebird bio Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
43%
Over the last year, the Other Long-Term Assets growth was -3%. The average annual Other Long-Term Assets growth rates for bluebird bio Inc have been -12% over the past three years , 4% over the past five years , and 43% over the past ten years .